International Stem Cell Corporation (OTCBB:ISCO), www.internationalstemcell.com,
announced today that its wholly owned subsidiary Lifeline Skin Care,
Inc. ("LSC"), has now completed its evaluation of the highly successful
trial launch of its new stem cell skin care product line in November and
December 2010, and will move forward with its general marketing program.
Lifeline Skin Care products contain parthenogenetic stem cell extract
and were developed by the ISCO research team in collaboration with world
recognized cosmetic chemists. The breakthrough products deliver leading
advances in skin rejuvenation technology that help to prevent and repair
damaged skin. The products are available through our online store at www.lifelineskincare.com.
"Sales to date have greatly exceeded our expectations for the trial
launch. These initial sales resulted from a very limited product
offering made to subscribers of only one of the several newsletters of
our marketing partner, John Mauldin, plus a small direct mailing to
interested parties and ISCO's shareholders who had signed up for general
corporate information through the ISCO website," said Dr. Ruslan
Semechkin, CEO of Lifeline Skin Care.
Lifeline Skin Care is now ready to move forward to the next phase of
distribution, which will commence near the end of March. That phase will
consist initially of a customer solicitation conducted by John Mauldin's
specialty Internet and direct response marketing organization. "We
almost never endorse or sell a retail product," said Mr. Mauldin, "but
the results of both our informal testing and the company's formal
studies have convinced us that the Lifeline Skin Care products really
are a game-changing advance in skin care. I have not seen such a strong
response in online marketing in the last ten years. We are all very
excited and proud to be involved."
Kenneth Aldrich, Chairman of ISCO, issued a cautionary comment to its
investors. "We are incredibly excited by the prospects of this new
product from our Lifeline Skin Care subsidiary. Selling over 7,000
bottles through a very limited trial launch, as we have done, represents
a significant first step, but it would be imprudent for us to base
projections of future sales or profits on a sample base of this size."
ISCO investors should note that under ISCO's current revenue recognition
policy, a large portion of the Q-4 2010 sales will not be included as
revenue in the financial statements for the year ended December 31,
2010. Sales of these products meet our revenue recognition criteria
after our 30 day product guarantee period has been completed.
ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)
International Stem Cell Corporation is a California-based biotechnology
company focused on therapeutic and research products. ISCO's core
technology, parthenogenesis, results in creation of pluripotent human
stem cells from unfertilized oocytes (eggs). These proprietary cells
avoid ethical issues associated with use or destruction of viable human
embryos and, unlike most other major stem cell types, can be immune
matched and be a source of therapeutic cells with minimal rejection
after transplantation into hundreds of millions of individuals of
differing racial groups. ISCO also produces and markets specialized
cells and growth media for therapeutic research worldwide through its
subsidiary, Lifeline Cell Technology, and has developed cell based skin
care products through its subsidiary, Lifeline Skin Care. ISCO is
advancing novel human stem cell-based therapies where cells have been
proven to be efficacious but traditional small molecule and protein
therapeutics have not. More information is available on ISCO's website, www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications please click on
the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
FORWARD-LOOKING STATEMENTS
Statements pertaining to anticipated developments, product marketing
plans, the potential benefits of collaborations, affiliations, and other
opportunities for the company and its subsidiaries, along with other
statements about the future expectations, beliefs, goals, plans, or
prospects expressed by management constitute forward-looking statements.
Any statements that are not historical fact (including, but not limited
to statements that contain words such as "will," "believes," "plans,"
"anticipates," "expects," "estimates,") should also be considered to be
forward-looking statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, risks inherent in the
development and/or commercialization of potential products and the
management of collaborations, regulatory approvals, need and ability to
obtain future capital, application of capital resources among competing
uses, and maintenance of intellectual property rights. Actual results
may differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together with
the many uncertainties that affect the company's business, particularly
those mentioned in the cautionary statements found in the company's
Securities and Exchange Commission filings. The company disclaims any
intent or obligation to update forward-looking statements.
Key Words: Stem cells, parthenogenesis, biotechnology, skin care
International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
1-760-940-6383
kaldrich@intlstemcell.com
or
Lifeline
Skin Care, Inc.
Ruslan Semechkin, PhD, President & CEO
Vice
President, ISCO
ras@intlstemcell.com |
